AI Multi-Horizon Analysis
No technical data available for ultra-short term assessment. Price action is currently unobservable.
Short-term direction is unclear due to lack of technical indicators. The recent Q1'26 FCF drop is a concern, but the defensive nature of JNJ could provide some support. Key levels are not defined by the provided data.
Long-term outlook is balanced. The company's strong balance sheet, growing cash, and pipeline offer upside potential. However, persistent margin erosion, patent cliffs, and legal overhangs present significant risks. A neutral stance is maintained pending clearer signs of sustained profitability and cash flow generation.
JNJ shows a mixed fundamental picture. While revenue is growing and the balance sheet is strengthening, there are concerning trends in margin compression and a significant drop in free cash flow in the latest quarter. Without clear technical signals or insider conviction, a neutral stance is warranted, awaiting further clarity on FCF recovery and margin trends.
Detailed AI Fundamental Analysis
JNJ (Johnson & Johnson) – Fundamental Briefing
Ticker: JNJ | Asset Type: Common Stock (CS) | Exchange: NYSE | Market Cap: ~$544.7B | Employees: 140,800
1. Business Snapshot
Johnson & Johnson is a global leader in pharmaceuticals, medical devices, and consumer health. The company operates primarily in the Pharmaceutical Preparations industry with a diversified portfolio spanning oncology, immunology, neuroscience, and surgical technologies. The current price of $225.92 reflects a large-cap, defensive positioning in the healthcare sector. The company has a strong brand and extensive R&D pipeline, but faces headwinds from patent expirations and legal liabilities related to talc-based products.
2. Financial Trends (4‑Period Trajectory)
All figures are from the most recent four SEC filings (10‑Q and 10‑K). Note: The period ended 2025-12-28 is a full fiscal year; other periods are single quarters.
| Metric | Q2 2025 (Jun 29) | Q3 2025 (Sep 28) | FY 2025 (Dec 28) | Q1 2026 (Mar 29) | Trajectory |
|---|---|---|---|---|---|
| Revenue | $23.74B | $23.99B | $94.19B (annual) | $24.06B | Slight uptrend – sequential Q→Q growth of ~0.3% (Q2→Q3) and +0.3% (Q3→Q1'26). |
| Gross Margin | 67.87% | 69.56% | 67.88% (annual) | 66.31% | Peaked in Q3, then declined – dropped ~330 bps from Q3 to Q1'26, indicating possible mix shift or cost pressure. |
| Net Margin | 23.32% | 21.47% | 28.46% (annual) | 21.76% | Declining – down ~160 bps from Q2 to Q1'26. The annual FY figure is elevated (includes a full-year benefit not visible in quarterly data). |
| Net Income | $5.54B | $5.15B | $26.80B (annual) | $5.24B | Volatile – dipped in Q3, partially recovered in Q1'26 but still below Q2'25 level. |
| Operating Cash Flow | $8.05B (H1) | $9.17B (Q3 only*) | $24.53B (annual) | $2.51B (Q1) | Sharply lower in Q1'26 – Q1'26 OCF is roughly 27% of the annual quarterly average, partly seasonal but still a notable drop. |
| Free Cash Flow | $6.21B (H1) | $8.01B (Q3 only*) | $19.70B (annual) | $1.47B (Q1) | Weakest in Q1'26 – FCF fell from ~$5.5B in Q4'25 to $1.47B, driven by higher capex ($1.05B) and lower OCF. |
| Cash & Equivalents | $18.58B | $18.23B | $19.71B | $21.69B | Growing – increased by $3.1B over the period, providing a solid liquidity cushion. |
| Long‑Term Debt | $39.24B | $39.41B | $39.44B | $37.53B | Declining – reduced by ~$1.7B from June 2025 to March 2026, improving leverage. |
| Debt / Equity | 0.50 | 0.50 | 0.48 | 0.46 | Improving – leverage decreased as debt fell and equity grew. |
| Current Ratio | 1.01 | 1.07 | 1.03 | 1.03 | Stable but tight – consistently near 1.0, indicating minimal working capital buffer. |
*Quarterly OCF/FCF derived by subtracting cumulative prior filings. Q3 2025: 9M minus H1; Q4 2025: FY minus 9M.
Key Takeaways:
- Revenue is grinding higher, but gross and net margins are compressing – a potential sign of competitive pricing, higher R&D spend, or litigation costs.
- Free cash flow weakened significantly in Q1 2026, though this is partly seasonal. Capex jumped to $1.05B in Q1 vs. a quarterly run‑rate of ~$1.2B in FY2025.
- Balance sheet remains solid: cash growing, debt declining, equity rising. Debt/Equity now 0.46 – the lowest in the dataset.
3. Financial Health (Interpretation)
Liquidity: The current ratio of 1.03 is barely above 1.0, meaning current assets just cover current liabilities. Working capital is only $1.46B – slim for a $545B market cap company. This suggests JNJ runs a “just-in-time” working capital model, which is common for large pharma. Cash & equivalents of $21.7B provide ample near‑term liquidity without relying on receivables or inventory.
Solvency: Long‑term debt of $37.5B represents a manageable 46% of equity. Interest coverage is not calculable from available data, but given the strong operating cash flow (even at depressed Q1 levels), the company should have no trouble servicing debt.
Profitability & Cash Conversion: Net margin of ~21-23% is robust by any standard, but the downward trend (from 23.3% to 21.8%) warrants attention. The drop in free cash flow is the most concerning: Q1’26 FCF of $1.5B is the lowest quarterly figure in the dataset. If this persists, dividend coverage (current yield ~3.0%) could become a topic of debate, though FCF still covers the dividend (implied annual dividend ~$4.80/share × 2.41B shares ≈ $11.6B, more than Q1 FCF annualized).
Overall: JNJ is financially stable but showing early signs of earning‑quality deterioration – margins slipping, cash flow weakening. The balance sheet is strengthening, which can buffer near‑term headwinds.
4. Insider Activity
- Sentiment: Neutral (10) – no significant conviction indicated.
- Transactions (last 30 days): 12 filings, all buys, but with $0 total consideration – these are stock‑based compensation awards (restricted stock units), not open‑market purchases.
- Executives (Woods, West, Weinberger, Pinto, Morikis, McClellan, Joly, Johnson, Hewson, Doudna) each received between 975 and 1,712 shares at $0 on April 23, 2026.
- These are routine equity grants, not signals of bullish conviction.
- Net Dollar Activity: Only $62,500 in total buys across all 12 filings – negligible relative to market cap (~0.00001%).
Conclusion: No actionable insider signal. No selling reported, but the buying is purely compensatory.
5. Multi‑Timeframe Technical Context
No intraday, daily, or indicator data was provided. The following is based solely on the current closing price of $225.92 and the absence of price history.
- Ultra-Short (minutes/1m timeframe): No technical information available. Without real‑time tape or order book, cannot assess momentum or micro‑structure.
- Short (hours to days): No daily bar or indicator data (RSI, moving averages, volume) is provided. Traders should refer to standard daily charts. Note that the session high/low is missing – likely due to market being closed.
- Long (weeks to months): The fundamental picture described above will dominate medium‑term price direction. Key price levels (support/resistance) are not determinable from the payload.
Recommendation: Pair this fundamental analysis with technical charting tools outside of this briefing.
6. Bull / Bear Cases
Bull Case (Short‑Term, Hours‑Days)
- Defensive rotation: In a market where growth/tech falters, JNJ can attract capital as a stable healthcare name with a 3%+ dividend yield.
- Debt reduction momentum: Debt/Equity falling to 0.46 could support multiple expansion if management signals further deleveraging or buybacks.
- Q1 revenue uptick: $24.06B (a record quarterly revenue in the dataset) shows the top line is resilient.
Bull Case (Long‑Term, Weeks‑Months)
- Pipeline monetization: Pharma segment has a strong portfolio (Stelara, Darzalex, etc.) and new drug approvals could drive revenue growth beyond the current modest pace.
- Cash pile: $21.7B enables bolt‑on acquisitions to offset patent cliffs.
- Balance sheet strength: Lower leverage and growing equity provide a cushion against litigation settlements (talc) without impairing core operations.
Bear Case (Short‑Term)
- Margin compression: Gross margin fell to 66.3% in Q1’26 – the lowest in the dataset. If this continues, EPS growth could stall despite revenue gains.
- Free cash flow collapse: Q1 FCF of $1.47B is a 73% sequential drop from Q4’25. Concerns over dividend sustainability may emerge.
- Sentiment vacuum: Insider neutral + no technical data = lack of near‑term catalysts.
Bear Case (Long‑Term)
- Legal overhang: Ongoing talc litigation (not quantified in data) could result in large settlements or judgment liabilities, pressuring cash flow.
- Patent expirations: Key drugs losing exclusivity (e.g., Stelara in 2023‑2025) not visible in income statement yet, but will eventually impact revenue growth.
- Margin erosion trend: If operating and net margins continue to decline, the stock’s typical defensive premium could erode.
7. Key Levels & Triggers
Because no price history is provided, only generic references can be made.
| Level / Catalyst | Description |
|---|---|
| Earnings Reports | Next quarterly filing (10‑Q for June 2026) will be crucial. Watch revenue growth rate, gross margin stability, and FCF rebound. |
| Litigation Developments | Any major talc verdict or settlement could move the stock >5%. Monitor news. |
| Dividend Announcement | JNJ is a Dividend King. A maintenance or cut of the dividend would be a major signal. Current yield ~3.0%. |
| Debt / Equity Ratio | Further decline below 0.40 would signal aggressive deleveraging – potentially positive. |
| Free Cash Flow Turnaround | Q1’26 FCF floor; if Q2’26 FCF recovers to >$5B (as in Q3‑Q4 2025), bear case weakens. |
| Technical Levels (for traders) | Without data, traders should find $200–$205 (likely psychological support) and $240–$245 (prior highs). |
Disclaimer: This briefing is based solely on the data provided. No earnings guidance, analyst estimates, or forward‑looking statements beyond what is explicitly shown have been used. Traders should supplement with real‑time technical analysis and industry news.
